Biobot Surgical, a Singapore-based medical technology company developing robotic-assisted systems for prostate cancer diagnosis and treatment, has secured S$20 million ($15.4 million) in its latest financing round led by ClavystBio in partnership with ZIG Ventures.

In a statement on Monday, ClavystBio said the funding will accelerate adoption of the company’s Mona Lisa platform, which integrates robotic needle guidance and MRI-ultrasound image fusion for targeted prostate biopsy and focal ablation, across international markets. It will also support entry strategy for the United States market , expand the company’s clinical and economic evidence base, and strengthen commercial capabilities for its next phase of growth.

Biobot has deployed more than 80 systems globally and supported more than 30,000 patients, with adoption across leading centers in Europe and Asia Pacific. The company’s evidence base includes more than 50 real-world clinical publications. Prostate cancer affects more than 1.4 million men diagnosed annually worldwide.

As part of its US commercialization strategy, Biobot will work with Fogarty Innovation to define priority clinical segments and accelerate adoption among clinicians.

Anselm Tan, MedTech Lead at ClavystBio, said Biobot has the right combination of clinical relevance, international traction, and platform potential as the market moves toward prostate procedures that are safer, more precise, and more reproducible.

Sim Kok Hwee, Deputy Chairman and CEO of Biobot Surgical, said the company’s objective is to build Mona Lisa into a precision intervention platform for prostate care, connecting imaging, robotic guidance, procedure data, and focal treatment workflows. Its long-term strategy focuses on building repeatable models for adoption in settings where transperineally prostate procedures deliver the greatest clinical and economic value, the executive added.

Singapore unveils AI supercomputer to advance climate, healthcare studies